



# Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Allison A. Feduccia<sup>1</sup> · Lisa Jerome<sup>2</sup> · Michael C. Mithoefer<sup>2,3</sup> · Julie Holland<sup>4</sup>

Published online: 10 August 2024  
© The Author(s) 2024

**Retraction Note: Psychopharmacology (2020) 238:581–588**  
<https://doi.org/10.1007/s00213-020-05710-w>

The Editors have retracted this article after they were informed of protocol violations amounting to unethical conduct at the MP4 study site by researchers associated with this project. The authors have subsequently confirmed that they were aware of these violations at the time of submission of this article, but did not disclose this information to the journal or remove data generated by this site from their analysis. Additionally, the authors also did not fully declare a potential competing interest. Two of the authors are affiliated with the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC), a subsidiary that is wholly owned by the Multidisciplinary Association for Psychedelic Studies (MAPS). As is stated in the Funding declaration, MAPS fully funded and provided the MDMA that was used in this trial, and MAPS PBC organized the trial.

Allison A. Feduccia agrees with this retraction but disagrees with the wording of the retraction notice. Lisa Jerome, Michael C. Mithoefer, and Julie Holland disagree with this retraction.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s00213-020-05710-w>.

---

✉ Allison A. Feduccia  
afeduccia@gmail.com

- <sup>1</sup> Psychedelic.Support, Project New Day, Santa Cruz, CA, USA
- <sup>2</sup> MAPS Public Benefit Corporation, Santa Cruz, CA, USA
- <sup>3</sup> Medical University of South Carolina, Charleston, SC, USA
- <sup>4</sup> Private Practice, New York, NY, USA